Harrow (NASDAQ:HROW) Posts Earnings Results, Beats Expectations By $0.06 EPS

Harrow (NASDAQ:HROW) posted its quarterly earnings data on Monday. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06, FiscalAI reports. The company had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 68.20%.

Harrow Price Performance

Shares of NASDAQ:HROW traded down $1.18 during trading on Wednesday, reaching $29.18. 406,008 shares of the company traded hands, compared to its average volume of 696,680. The company has a quick ratio of 2.08, a current ratio of 2.24 and a debt-to-equity ratio of 19.70. Harrow has a 52 week low of $25.76 and a 52 week high of $54.85. The firm has a market capitalization of $1.09 billion, a PE ratio of -37.41 and a beta of 0.18. The company’s 50 day moving average is $31.30 and its two-hundred day moving average is $37.74.

Analyst Ratings Changes

A number of research analysts recently weighed in on HROW shares. Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Friday, October 16th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. BTIG Research restated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday. Finally, Leerink Partners assumed coverage on shares of Harrow in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.17.

Insider Buying and Selling

In related news, insider Amir Shojaei sold 11,250 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider owned 11,250 shares of the company’s stock, valued at $450,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 12.80% of the stock is currently owned by company insiders.

Key Headlines Impacting Harrow

These are some of the HROW headlines that stood out recently:

• Positive Sentiment: Q3 revenue reached a record $99.3 million, up 39% year over year, led by branded-product revenue growth of 62%. The company also reported $9.8 million in GAAP net income, although that figure included a $5.0 million litigation-settlement gain. Harrow Q3 2026 financial results
• Neutral Sentiment: Harrow reaffirmed full-year 2026 revenue guidance of $350 million to $365 million, roughly in line with the cited analyst consensus. Q4 revenue guidance is $136 million to $151 million. Harrow earnings guidance
• Negative Sentiment: The key concern is profitability guidance: Harrow lowered its full-year 2026 adjusted EBITDA outlook to more than $40 million from $80 million to $100 million previously. Q3 adjusted EBITDA was $21.2 million, below $22.8 million a year earlier, making the outlook reset a notable bearish counterweight to record revenue. Harrow Q4 revenue and EBITDA outlook

About Harrow

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.